RA0441

antibody from Oursmab

Targeting: KIR3DL2 CD158K, cl-5, nkat4, nkat4a, nkat4b

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0441

Provider

Oursmab

Product name

Lacutamab (Biosimilar Reference Antibody) (KIR3DL2)

Antibody type

Monoclonal

Description

Lacutamab (formerly IPH4102) is an investigational, first-in-class humanized monoclonal antibody that targets KIR3DL2, an inhibitory receptor belonging to the killer cell immunoglobulin-like receptor (KIR) family. KIR3DL2 is selectively and highly expressed on the malignant T cells in certain cutaneous T-cell lymphomas (CTCL), particularly S¨¦zary syndrome and mycosis fungoides. By binding to KIR3DL2, Lacutamab is designed to induce antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), leading to the targeted elimination of the malignant T cells. It represents a promising tumor-selective immunotherapy for these rare and aggressive lymphomas.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.